Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes.
Jonathan Mitry HyakYing HuangKerry A RogersSeema A BhatMichael R GreverJohn C ByrdAdam S KittaiDaniel M JonesCecelia R MillerJennifer A WoyachPublished in: Blood advances (2022)